- Home
- NPT vs LSTA Comparison
NPT vs LSTA Comparison
Compare NPT & LSTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NPT | LSTA |
|---|---|---|
| Founded | 2011 | 1980 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Specialty Chemicals | Misc Health and Biotechnology Services |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 29.7M | 28.9M |
| IPO Year | N/A | 2000 |
Fundamental Metrics
Financial Performance| Metric | NPT | LSTA |
|---|---|---|
| Price | $2.31 | $3.47 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $15.00 |
| AVG Volume (30 Days) | ★ 7.5M | 105.0K |
| Earning Date | 05-23-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 20.42 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $35,283,868.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 56.90 |
| 52 Week Low | $1.14 | $1.81 |
| 52 Week High | $22.38 | $5.07 |
Technical Indicators
Market Signals| Indicator | NPT | LSTA |
|---|---|---|
| Relative Strength Index (RSI) | 49.20 | 51.45 |
| Support Level | $1.19 | $3.06 |
| Resistance Level | $6.15 | $3.67 |
| Average True Range (ATR) | 1.18 | 0.14 |
| MACD | 0.12 | 0.01 |
| Stochastic Oscillator | 9.00 | 24.32 |
Price Performance
Historical ComparisonAbout NPT Texxon Holding Limited Ordinary shares
Texxon Holding Ltd provides technology-enabled supply chain management services to customers in the plastics and chemical industries in East China. The company operates through two segments: Supply Chain Trading and Plastic Manufacturing. Its services include procurement, logistics, payments, and fulfillment for Chinese SMEs, and all revenue is generated from operations within the People's Republic of China.
About LSTA Lisata Therapeutics Inc.
Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The company has one operating segment, the research and development of its investigational drug product.